Corcept rises after FDA approves ovarian cancer drug

Corcept Therapeutics Incorporated

25/03/2026 15:43

** Shares of drugmaker Corcept Therapeutics CORT.O rise 27.4% to $43.09

** Stock set for biggest daily percentage rise in nearly a year, if gains hold

** U.S. Food and Drug Administration approves co's drug, relacorilant, branded as Lifyorli, for an aggressive form of ovarian cancer

** Agency says drug is to be used in combination with a chemotherapy drug, nab-paclitaxel, for the treatment of platinum-resistant epithelial ovarian cancer, a type of cancer that returns or continues to grow within about six months after treatment with platinum-based chemotherapy

** FDA's approval was based on a 381-patient trial, where participants on the combination therapy lived a median of 16 months, compared with 11.9 months on chemotherapy alone

** Lifyorli works by blocking cortisol-related signals, which can help make tumors more responsive to chemotherapy

     ** CORT fell more than 30% in 2025

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))